ElectroMotive Drug Administration (EMDA) of Mitomycin C as First-Line Salvage Therapy in High Risk “BCG Failure” Non Muscle Invasive Bladder Cancer: 3 Years Follow-Up Outcomes
BMC Cancer - United Kingdom
doi 10.1186/s12885-018-5134-7
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2018
Authors
Publisher
Springer Science and Business Media LLC